Cargando…

A Case of Double Expresser Diffuse Large B Cell Lymphoma Treated with R-CODOX-M/R-IVAC

Diffuse Large B Cell Lymphoma (DLBCL) is a heterogeneous disease with a variety of chromosomal abnormalities contributing to differences in management. While it is known that Double Hit Lymphomas (DHL) warrant more aggressive chemotherapy regimens, debate remains on how to treat Double Expresser Lym...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bemis, Thomas, Ioanitescu, Jonathan, Mackovick, Lynn, Hammad, Azzam, Rubin, Jascha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738241/ https://www.ncbi.nlm.nih.gov/pubmed/31543774 http://dx.doi.org/10.1159/000502087

Ejemplares similares

Treatment of grey zone lymphoma using the R-CODOX-M/R-IVAC protocol: Two case reports
por: Yang, Xiao-Yan, et al.
Publicado: (2017)

Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma
por: Chen, Meiting, et al.
Publicado: (2021)

Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial()
por: McMillan, A.K., et al.
Publicado: (2020)

HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era
por: Rodrigo, J. A., et al.
Publicado: (2012)

Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial
por: Phillips, Elizabeth H., et al.
Publicado: (2020)

Modified dose intensive R- CODOX-M/IVAC for HIV-associated burkitt (BL) (AMC 048) shows efficacy and tolerability, and predictive potential of IRF4/MUM1 expression
por: Noy, Ariela, et al.
Publicado: (2012)

Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.
por: Devi, Kanta, et al.
Publicado: (2021)

Complications and outcomes in diffuse large B‐cell lymphoma with gastric lesions treated with R‐CHOP
por: Kadota, Tomohiro, et al.
Publicado: (2019)

Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma
por: Choi, Soyeon, et al.
Publicado: (2022)

Case Report First-in-Man Method Description: Left Ventricular Unloading With iVAC2L During Veno-Arterial Extracorporeal Membrane Oxygenation: From Veno-Arterial Extracorporeal Membrane Oxygenation to ECMELLA to EC-iVAC®
por: Tschöpe, Carsten, et al.
Publicado: (2020)

Influence of NK cell count on the survival of patients with diffuse large B-cell lymphoma treated with R-CHOP
por: Kim, Joong-Keun, et al.
Publicado: (2014)

Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy
por: Hong, Junshik, et al.
Publicado: (2014)

Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14
por: Gutiérrez, Antonio, et al.
Publicado: (2015)

miR-4284 and miR-4484 as Putative Biomarkers for Diffuse Large B-Cell Lymphoma
por: Tamaddon, Gholamhossein, et al.
Publicado: (2016)

The Modified Glasgow Prognostic Scores as a Predictor in Diffuse Large B Cell Lymphoma Treated with R-CHOP Regimen
por: Kim, Yundeok, et al.
Publicado: (2014)

Construction and Validation of a Novel Nomogram for Predicting the Recurrence of Diffuse Large B Cell Lymphoma Treated with R-CHOP
por: Gong, Yuxi, et al.
Publicado: (2023)

Effectiveness and Safety of a Prolonged Hemodynamic Support by the IVAC2L System in Healthy and Cardiogenic Shock Pigs
por: Delmas, Clément, et al.
Publicado: (2022)

PD-L1 and miR-34a are Prognostic Factors for Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP
por: Wang, Jinfeng, et al.
Publicado: (2020)

PB2119: LONG-TERM SURVIVAL PROJECTIONS OF LONCASTUXIMAB TESIRINE-TREATED PATIENTS IN RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Hamadani, M., et al.
Publicado: (2022)

R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms
por: Wang, Liang, et al.
Publicado: (2021)

Blood Lymphocyte-to-Monocyte Ratio Identifies High-Risk Patients in Diffuse Large B-Cell Lymphoma Treated with R-CHOP
por: Li, Zhi-Ming, et al.
Publicado: (2012)

The international staging system improves the IPI risk stratification in patients with diffuse large B-cell lymphoma treated with R-CHOP
por: Wei, Xiaolei, et al.
Publicado: (2017)

Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy
por: Kang, Hye Jin, et al.
Publicado: (2020)

Predictive value of interim FDG-PET/CT findings in patients with diffuse large B-cell lymphoma treated with R-CHOP
por: Kitajima, Kazuhiro, et al.
Publicado: (2019)

P1159: INFERIOR OUTCOME OF FRAIL AND UNFIT PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ATTENUATED R-CHOP
por: Al-Sarayfi, Diana, et al.
Publicado: (2023)

Switching Fractioned R-CHOP Cycles to Standard R-CHOP Cycles Guided by Endoscopic Ultrasonography in Treating Patients with Primary Gastric Diffuse Large B-Cell Lymphoma
por: Liu, Yizhen, et al.
Publicado: (2020)

R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma
por: Lee, Hong Ghi, et al.
Publicado: (2014)

Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma
por: Yoo, Changhoon, et al.
Publicado: (2010)

Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation
por: Lee, Hong Ghi, et al.
Publicado: (2015)

ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP
por: Liu, Duo, et al.
Publicado: (2017)

High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients
por: Laursen, Maria Bach, et al.
Publicado: (2019)

Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP – the PLRG report
por: Drozd-Sokolowska, Joanna, et al.
Publicado: (2020)

The Prognostic Impact of Comorbidities in Patients with De-Novo Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy in Curative Intent
por: Kocher, Florian, et al.
Publicado: (2020)

Prognostic Value of Sarcopenia in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A Systematic Review and Meta-Analysis
por: Xu, Xin-Tian, et al.
Publicado: (2022)

Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP
por: Qin, Yan, et al.
Publicado: (2022)

How I treat diffuse large B-cell lymphoma
por: Melchardt, T., et al.
Publicado: (2023)

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S, et al.
Publicado: (2016)

PB2323: R-ESHAP VS R-ICE AS RESCUE TREATMENT IN DIFFUSE LARGE B-CELL LYMPHOMA. A SINGLE-CENTEREXPERIENCE.
por: Pérez-Pinilla, Belén, et al.
Publicado: (2023)

Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens
por: Zhang, Fangwen, et al.
Publicado: (2019)

Chromosomal abnormality variation detected by G‐banding is associated with prognosis of diffuse large B‐cell lymphoma treated by R‐CHOP‐based therapy
por: Mizuno, Yoshimi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8lt39c781qvnsn1bnp3f6o6s6i